Anthony Chalmers University of Glasgow
|
|
- Claude Morton
- 5 years ago
- Views:
Transcription
1 Radiotherapy-drug combinations for NSCLC: current and potential UK collaborative initiatives Anthony Chalmers University of Glasgow UK SABR Consortium 25th November 2016
2 Increase tumour control and cure rates by combining molecular targeted agents with precision radiotherapy
3 Surviving fraction 66 Gy in Gy in 20 SABR Radiation dose per (Gy)
4 Why combine drugs with SABR? Improve local control
5
6 Why combine drugs with SABR? Improve local control Large tumours? Adverse dosimetry? Adverse biology?? Systemic effects Only if SABR will enhance systemic effects Immunomodulators Bystander effects? Reduce normal tissue toxicity
7 Which drugs to combine with RT and/or SABR? Improve local control Systemic effects Reduce normal tissue toxicity
8
9
10 Late responding normal tissues Base Excision Repair PARP ATM, ATR Chk1, Chk2 Tumour G 1 S G 2 M Nonhomologous end-joining ATM Homologous recombination
11 s u rv iv in g fra c tio n E 2 C S C E 2 C S C P A R P i E 2 C S C A T R i E 2 C S C A T M i E 2 C S C C h k 1 i E2 primary GBM stem cell cultures Ahmed SU, Carruthers R et al Cancer Research G y Calu6 lung adenocarcinoma subcutaneous xenografts Andy Ryan, Oxford unpublished data
12 Immune checkpoint inhibitors Courtesy: Inge Verbrugge Larson et al. Nat Rev Cancer 2015
13 Why have so few radiotherapy-drug combinations been approved?
14 Commercial gain from drug Additional factors: Slow trial set-up and recruitment Fear of exacerbating normal tissue toxicities Lack of consensus over RT standard of care Uncertainties over route to registration and regulatory approval processes Commercial gain from drug-rt combination
15 What can we do about it?
16 CTRad: Clinical and Translational Radiotherapy Research Working Group CTRad Executive Group WS1 (science base) WS2 (phase I/II) WS3 (phase III/ methodology) WS4 (new technology, physics, QA) Consumers RaDCom Biomarker Support Network Preclinical QA group RADCAS Advanced RT Trials proposals meetings RTTQA Protons Molecular RT Database development Academic work force development
17 Strength in numbers: 82 members Diversity, knowledge and expertise to make a difference
18 CTRad: How to get involved 1. Pass the limbo test 2. Perform a solo dance routine
19 Strength in numbers: 82 members Diversity, knowledge and expertise to make a difference
20 CTRad: Other ways to get involved 1. Clinical trials methodology workshops Annual event jointly run with RCR 2. Trials sandpit days For junior clinicians and investigators Convert a study idea into a research proposal 3. Proposals guidance meetings Twice yearly events (June, November) Obtain expert feedback and advice on clinical trial proposals Prepare for funding applications 58 clinical trials successfully funded to date
21 CTRad: Clinical and Translational Radiotherapy Research Working Group CTRad Executive Group WS1 (science base) WS2 (phase I/II) WS3 (phase III/ methodology) WS4 (new technology, physics, QA) Consumers RaDCom Biomarker Support Network Preclinical QA group RADCAS Advanced RT Trials proposals meetings RTTQA Protons Molecular RT Database development Academic work force development
22 Radiotherapy-Drug Combinations Consortium: RaDCom Providing preclinical evidence for early phase clinical trials Collaborative network of labs delivering quality preclinical efficacy data Partnership with industry, CRUK and other funding bodies Key point of contact for industrial partners seeking appropriate expertise Chair: Kaye Williams Co-chairs Workstream 1 Nicola Curtin (Newcastle) Susan Short* (Leeds) Co-chairs Workstream 2 Richard Adams* (Cardiff) Ricky Sharma* (Oxford) Theme Leads DNA damage response: Anthony Chalmers* (Glasgow) Signalling pathways: Anderson Ryan (Oxford) Tumour microenvironment: Kaye Williams (Manchester) Tumour metabolism: JSC Prioritisation Immunotherapy: Biological therapies: Patient representative: Ian Stratford (Manchester) Tim Illidge* (Manchester) Susan Short* (Leeds) Helen Bulbeck * clinician
23 Working with Industry EXPERTISE AND ADVICE Industry often have limited internal expertise in radiation therapy Require advice on normal tissue toxicity and experimental design ACTIVE COLLABORATIONS PRELIMINARY DISCUSSIONS Encouraging and facilitating evaluation of radiotherapy-drug combinations earlier in drug development pipeline
24 Quantifying normal tissue toxicity Radiation induced lung fibrosis Oesophagitis Skin erythema Andy Ryan, Oxford; unpublished data
25 CTRad: Clinical and Translational Radiotherapy Research Working Group CTRad Executive Group WS1 (science base) WS2 (phase I/II) WS3 (phase III/ methodology) WS4 (new technology, physics, QA) Consumers RaDCom Biomarker Support Network Preclinical QA group RADCAS SABR Trials proposals meetings RTTQA Protons Molecular RT Database development Academic work force development
26 Sharma et al, Nature Reviews Clinical Oncology, 2016
27 PRIMING: Pembrolizumab with SBRT for Advanced NSCLC Primary Endpoint: PI: Dr McDonald To establish MTD and RP2D that can be safely combined with ablative 3# thoracic SBRT. Week Run-in Phase of Pembrolizumab RT Phase: 54 Gy in 3 # over 1 week Post-RT Phase: Pembrolizumab D1 100 mg / D2 200 mg q3w 200mg q3w Pembrolizumab
28 MESO-PRIME: Pembrolizumab with SBRT for Malignant Mesothelioma Primary Endpoint: PI: Dr McDonald & Dr Harrow To establish MTD and RP2D that can be safely combined with ablative 5# thoracic SBRT. Week Run-in Phase of Pembrolizumab RT Phase: 55 Gy in 5 # over 2 week Post-RT Phase: Pembrolizumab D1 100 mg / D2 200 mg q3w 200mg q3w Pembrolizumab
29 PARIS: Pembrolizumab with Radical Radiotherapy for LA NSCLC Primary Endpoint: PI: Prof Faivre-Finn To establish MTD and RP2D that can be safely combined with conventional radical RT following chemotherapy. Week Platinum Chemotherapy Phase Run-in Phase of Pembrolizumab RT Phase: Gy in # w Post-RT Phase: Pembrolizumab D mg / D1 200 mg q3w 200mg q3w Pembrolizumab
30 SABR PARP- A phase I study of rucaparib and stereotactic ablative body radiotherapy (SABR) to the lung in the treatment of oligometastatic disease Improve local control Particularly if defects in BRCA, FA or HR pathways Protect normal lung tissue Reduction in normal lung tissue toxicity Improve distant control Enhanced bystander/ abscopal effects Extensive in vitro and in vivo data showing radiosensitising effects of PARPi Phase 1 trials ongoing combining PARPi & conventional external beam XRT
31 Separate phase I trials testing single RT-drug combinations are highly inefficient
32 Multiple overlapping and/or competing proposals submitted to CTRad for RT-drug combinations in non-small cell lung cancer Lack of consensus over radiotherapy backbone regime Fragmented approach Two day workshop in Glasgow, February 2016 Clinicians, statisticians, scientists, consumers, pharma
33 Phase I multi-arm drug dose escalation study of DNA repair inhibitors in combination with radical RT for stage III NSCLC Trial Development Group Lead Scientist (Lung CSG SLWG) Clinical Oncology CI Medical Oncology CI Clinical Trials Unit Lead Statistician Drug A Gy CI Drug B Gy CI Drug C Gy CI Drug D Gy CI Gy control arm CI s Gerry Hanna (Belfast), Alistair Greystoke (Newcastle) Leeds Clinical Trials Unit, Sarah Brown lead statistician
34 Stage III study design Patients fit for radical RT but not concomitant chemort (sequential chemo permitted but not required) Performance status 0-2 RT dose in 30# determined by normal tissue constraints Initially, drugs from AZ DDRi portfolio (olaparib, Wee1i, ATRi, ATMi); additional drugs could be added Initally, patients randomly allocated to each arm If biomarkers become available, enrich relevant arm(s) with biomarker+ patients
35 Phase II multi-arm study of immunomodulatory agents in combination with RT for stage IV NSCLC Trial Development Group Lead Scientist (Lung CSG SLWG) Clinical Oncology CI Medical Oncology CI Standard chemotherapy Clinical Trials Unit Lead Statistician Palliative RT indicated Palliative RT not indicated Drug A + RT Drug B + RT Drug C + RT RT alone Drug X alone Drug X + RT Drug Y alone Drug Y + RT CI s Fiona McDonald (RMH), Martin Forster (UCLH) ICR Clinical Trials Unit, Emma Hall lead statistician
36 Stage IV study design Patients with stage IV NSCLC (include stage III patients ineligible for radical treatment?) Standard chemotherapy followed by stratification based on indication for palliative RT Immunomodulatory drugs; phase I RT combination data will be available for several; emeging agents can be added Opportunity to compare different RT dose and fractionation schedules
37 Summary Compelling rationale to combine new drugs with RT Different issues but still valid for SABR Historically, pharma reluctant to support RT-drug combinations CTRad and UK clinical oncology community have become world leaders in this area Pre-clinical expertise and organisation RaDCom Route to Registration Consensus Guidelines Strong relationships with some pharma companies, supported by Combinations Alliance Consortium based approach to optimise efficiency, increase engagement and access, maximise scientific and clinical outputs
The National Radiotherapy Research Strategy
RCR Clinical Oncology: Inspiring Future Academics in Clinical Oncology The National Radiotherapy Research Strategy David Sebag-Montefiore Professor of Clinical Oncology and Health Research Honorary Consultant
More informationCombined modality treatment for NSCLC with N2 disease
Combined modality treatment for NSCLC with N2 disease Gerry Hanna Senior Lecturer and Consultant in Clinical Oncology Centre for Cancer Research and Cell Biology @gerryhanna E: g.hanna@qub.ac.uk Talk Outline
More informationAGENDA: FEBRUARY 22, 2018 INTRODUCTION
FDA-AACR-ASTRO Clinical Development of Drug-Radiotherapy Combinations Workshop with support from Cancer Research UK Combinations Alliance February 22-23, 2018 Bethesda, MD Purpose: There is great interest
More informationProgress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:
SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental
More informationDefining a research programme in advanced radiotherapy
Defining a research programme in advanced radiotherapy Dr Ann Henry Associate Professor in Clinical Oncology a.henry@leeds.ac.uk Leeds Radiotherapy Research Group 2008 Move to Bexley State of art equipment
More informationACCELERATING PROGRESS THROUGH COLLABORATION ACCELERATOR AWARD CASE STUDIES
ACCELERATING PROGRESS THROUGH COLLABORATION ACCELERATOR AWARD CASE STUDIES CRUK CENTRES NETWORK At Cancer Research UK we recognise the crucial role that infrastructure plays in creating a dynamic and responsive
More informationIon Beam Therapy should we prioritise research on helium beams?
Ion Beam Therapy should we prioritise research on helium beams? Stuart Green Medical Physics University Hospital Birmingham NHS Trust Follow-up from the EUCARD2 workshop, ION Beam Therapy: Clinical, Scientific
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationFuture Therapeutic Developments in Head and Neck Cancer
Future Therapeutic Developments in Head and Neck Cancer Professor Kevin Harrington Joint Head of Division of Radiotherapy and Imaging The Institute of Cancer Research/The Royal Marsden NIHR Biomedical
More informationHow effective is current clinical trial QA
How effective is current clinical trial QA Elizabeth Miles UK National RadioTherapy Trials QA (RTTQA) group Mount Vernon Cancer Centre United Kingdom ESTRO 35 29 April 3 May Turin, Italy Contents QA processes
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationNew Radiation Treatment Modalities in the Treatment of Lung Cancer
New Radiation Treatment Modalities in the Treatment of Lung Cancer David Perry, M.D. Chief, Radiation Oncology Medical Director, CyberKnife Radiosurgery Center Medstar Franklin Square Medical Center Definitions
More informationRadiation Therapy and Immunotherapy: New Frontiers
Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical
More informationDr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA???
Dr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA??? History of Radiotherapy 1895 Rontgen describes X-rays 1896 Becquerel radioactivity 1905 Radiation is used to treat tumours
More informationNRG Oncology Lung Cancer Portfolio 2016
NRG Oncology Lung Cancer Portfolio 2016 Roy Decker, MD PhD Yale Cancer Center Walter J Curran, Jr, MD Winship Cancer Institute of Emory University NRG Oncology Lung Cancer Selected Discussion Stage III
More informationSarcoma and Radiation Therapy. Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington
Sarcoma and Radiation Therapy Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington Objective: Helping you make informed decisions Introduction Process Radiation
More informationNIHR Supporting collaboration in life sciences research
NIHR Supporting collaboration in life sciences research Dr Matt Hallsworth - Head of External Relations, NIHR Office for Clinical Research Infrastructure (NOCRI) Research funders build capabilities and
More informationMODULATING TISSUE IMMUNITY INNOVATION WORKSHOP CALL FOR APPLICATIONS
MODULATING TISSUE IMMUNITY INNOVATION WORKSHOP CALL FOR APPLICATIONS 1 Modulating Tissue Immunity Innovation Workshop If you would like to transform the treatment of cancer and musculoskeletal conditions
More informationRadiation Therapy and Immunotherapy: New Frontiers
Radiation Therapy and Immunotherapy: New Frontiers May 12 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland-Bellefonte and Logan Regional Cancer Centers Assistant Professor of Therapeutic Radiology,
More informationESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY
ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune
More informationBIOMARKER DRIVEN EARLY PHASE ONCOLOGY CLINICAL TRIALS; CHALLENGES IN THE REAL WORLD SID KATUGAMPOLA CENTRE FOR DRUG DEVELOPMENT CANCER RESEARCH UK
BIOMARKER DRIVEN EARLY PHASE ONCOLOGY CLINICAL TRIALS; CHALLENGES IN THE REAL WORLD SID KATUGAMPOLA CENTRE FOR DRUG DEVELOPMENT CANCER RESEARCH UK Cancer; Some Sobering Thoughts Getting cancer is one of
More informationAdvances in external beam radiotherapy
International Conference on Modern Radiotherapy: Advances and Challenges in Radiation Protection of Patients Advances in external beam radiotherapy New techniques, new benefits and new risks Michael Brada
More informationPalliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased
Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased analysis Roel Schlijper Fellow Radiation Oncology BC Cancer, Prince George Disclosures No conflicts
More informationProstate Cancer in men with germline DNA repair deficiency
Prostate Cancer in men with germline DNA repair deficiency Bruce Montgomery, MD Professor, Medicine and Urology Univ Washington, Fred Hutchinson CRC VA Puget Sound HCS Disclosures Company Tokai, ESSA,
More informationPfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer
For immediate release June 3, 2017 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib
More informationRadiotherapy What are our options and what is on the horizon. Dr Kevin So Specialist Radiation Oncologist Epworth Radiation Oncology
Radiotherapy What are our options and what is on the horizon Dr Kevin So Specialist Radiation Oncologist Epworth Radiation Oncology Outline Advances in radiotherapy technique Oligo - disease Advancements
More informationClinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology
Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology Abdominal SBRT: Clinical Aspects Rationales for liver and pancreas SBRT
More informationBeyond PARP - Next Generation DDR Therapeutics
Beyond PARP - Next Generation DDR Therapeutics September 19, 2017 Safe Harbor Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking
More informationCombining chemotherapy and radiotherapy of the chest
How to combine chemotherapy, targeted agents and radiotherapy in locally advanced NSCLC? Dirk De Ruysscher, MD, PhD Radiation Oncologist Professor of Radiation Oncology Leuven Cancer Institute Department
More informationCiti s 13 th Annual Biotech Conference September 5, 2018
Citi s 13 th Annual Biotech Conference September 5, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they
More informationDevelopmental Therapeutics for HCC, Colorectal Cancer, and Pancreatic Cancer. Manish Sharma, MD Developmental Therapeutics Symposium April 20, 2018
Developmental Therapeutics for HCC, Colorectal Cancer, and Pancreatic Cancer Manish Sharma, MD Developmental Therapeutics Symposium April 20, 2018 Disclosure Information 23 rd Annual Developmental Therapeutics
More information2016 CRUK Lung Cancer Centre of Excellence Student/Postdoc Winter Workshop Programme
2016 CRUK Lung Cancer Centre of Excellence Student/Postdoc Winter Workshop Programme Thursday 1 st December 2016 09.15am 10.00am Registration and Refreshments 10.15am 10.30am Welcome 10.30am 11.15am Opening
More informationThe summit and its purpose
Sponsors: 1 The summit and its purpose The Translational Hearing Research Summit: Biological and Pharmacological Approaches was an international summit that gathered 159 delegates, from 14 countries to
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationPPI s Big Picture - How Can We Join The Dots?
PPI s Big Picture - How Can We Join The Dots? Richard Stephens ICPV Conference, Brighton, Sept 2012 The National Institute for Health Research Cancer Research Network (NCRN) is part of the NIHR Clinical
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationClinical Research in Rare Cancers. Friday 10 th February Matt Seymour & Nicola Keat
Clinical Research in Rare Cancers Friday 10 th February 2012 Matt Seymour & Nicola Keat Rare cancer is a common disease Rare Cancer : [prevalence
More informationInvestor Meetings October 2018
Investor Meetings October 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements
More informationRadiotherapy Physics and Equipment
Radiological Sciences Department Radiotherapy Physics and Equipment RAD 481 Lecture s Title: Introduction Dr. Mohammed EMAM Ph.D., Paris-Sud 11 University Vision :IMC aspires to be a leader in applied
More informationKaren Brown (University of Leicester)
Karen Brown (University of Leicester) Chemoprevention in October 2013. Basic Translational Early phase trials Late phase trials Epidemiology Unique multidisciplinary team with National Coverage Brings
More informationEarly Phase Combination Studies and Working with Industry
Early Phase Combination Studies and Working with Industry Professor Jeff Evans University of Glasgow CR-UK Beatson Institute Beatson West of Scotland Cancer Centre Glasgow ECMC Disclosures Honoraria /
More informationRadiotherapy Board - Intensity Modulated Radiotherapy (IMRT) in the UK: Current access and predictions of future access rates
Radiotherapy Board - Intensity Modulated Radiotherapy (IMRT) in the UK: Current access and predictions of future access rates 1 Society and College of Radiographers Institute of Physics and Engineering
More informationPalliative radiotherapy in lung cancer
New concepts and insights regarding the role of radiation therapy in metastatic disease Umberto Ricardi University of Turin Department of Oncology Radiation Oncology Palliative radiotherapy in lung cancer
More information2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationFuture of Diabetes Research in Europe JDRF Perspective
Future of Diabetes Research in Europe JDRF Perspective IMI-JDRF Diabetes Patient Meeting 20 May 2014 Brussels, Belgium Olivier ARNAUD, Pharm D JDRF European Research Director oarnaud@jdrf.org Future of
More informationSingle Technology Appraisal (STA)
Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response
More informationESMO-Christie Lung Cancer Course
SMO-Christie Lung Cancer Course Wednesday 12th - Friday 14th February 2014 ducation Centre (Dept 17), The Christie, Manchester, M20 4BX This event is a joint initiative between The uropean Society for
More informationThe Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
More informationCritical Clinical Updates
Critical Clinical Updates ASTRO Spring Refresher Course JW Marriott Hotel Ramesh Rengan MD PhD Department of Radiation Oncology Friday March 22, 2013 Learning Objectives At the conclusion of this activity,
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationNew Trials status update ATARI/NCRI
New Trials status update ATARI/NCRI Trial setting: advanced, recurrent gynaecological cancers clear cell, endometrioid, carcinosarcoma (ovarian and endometrial), cervical carcinoma Study Design: non-randomised,
More informationClinical Priorities & Clinical Research Agenda
Clinical Priorities & Clinical Research Agenda Dr. Robin Grant Consultant Neurologist BRAINTUMOURSYMPOSIU For healthcare professionals, p The Grand Central Ho tel, Glasg ow PROGRAMME 09.00 Co ffee & Reg
More informationThe timely delivery of radical radiotherapy: guidelines for the management of unscheduled treatment interruptions Fourth edition
The timely delivery of radical radiotherapy: guidelines for the management of unscheduled treatment interruptions January 2019 Contents Foreword 3 Executive summary 4 1. Introduction 6 2. Background 8
More informationORYX Translational Medicine. Dr. Bernard Huber/ CEO
ORYX Translational Medicine Dr. Bernard Huber/ CEO ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007 and located in Baldham/Munich, Germany
More informationThe 4th Christie Advanced Radiotherapy Summer School
The 4th Christie Advanced Radiotherapy Summer School Monday 1st - Thursday 4th July 2019 Education Centre (Dept. 17),,, M20 4BX Discover, discuss and debate recent advances in radiotherapy Course Organisers
More informationENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA
ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA Formigal, 28 de Junio de 2018 CÓMO DEFINÍAMOS EL ESTADIO
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationProstate Cancer Priority Setting Partnership. PROTOCOL June 2009
Prostate Cancer Priority Setting Partnership PROTOCOL June 2009 Purpose The purpose of this protocol is to set out the aims, objectives and commitments of the Prostate Cancer Priority Setting Partnership
More informationNCCN Guidelines for Hepatobiliary Cancers V Web teleconference on 10/24/17
Guideline Page and Request HCC-4 the American Society of Radiation Oncology (ASTRO): We recommend further clarification of the eligibility criteria for surgical resection and liver transplantation, respectively.
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationORYX Translational Medicine. Dr. Dr. Sven Rohmann/ CBDO
ORYX Translational Medicine Dr. Dr. Sven Rohmann/ CBDO ORYX Overview Ø ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007 and located in Baldham/Munich, Germany
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationFarhat Din University of Edinburgh
Farhat Din University of Edinburgh number cannot treat our way out of cancer Chris Wild, IARC PubMed 180000 160000 140000 120000 100000 80000 60000 40000 20000 0 1800 1850 1900 1950 2000 2050 Year cancer
More informationFarhat Din University of Edinburgh
Farhat Din University of Edinburgh number cannot treat our way out of cancer Chris Wild, IARC PubMed 180000 160000 140000 120000 100000 80000 60000 40000 20000 0 1800 1850 1900 1950 2000 2050 Year cancer
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationA New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton
More informationBig data vs. the individual liver from a regulatory perspective
Big data vs. the individual liver from a regulatory perspective Robert Schuck, Pharm.D., Ph.D. Genomics and Targeted Therapy Office of Clinical Pharmacology Center for Drug Evaluation and Research Food
More informationThe first North East Palliative Care Research Symposium feedback from workshops
The first North East Palliative Care Research Symposium feedback from workshops Questions posed during afternoon sessions: 1. What are the big palliative research questions a North East collaborative should
More informationORYX Translational Medicine. Dr. Bernard Huber / CEO
ORYX Translational Medicine Dr. Bernard Huber / CEO BIO International Convention June 2016 ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007
More informationUpdate on PARP inhibitors: opportunities and challenges in cancer therapy
Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it
More informationOATech+ Network: Using Technology to work towards improving Patient Outcomes. Leanne Sawle
OATech+ Network: Using Technology to work towards improving Patient Outcomes Leanne Sawle Overview Osteoarthritis (OA) affects 8.75 million people in the UK (Mobasheri & Batt 2016) Places a considerable
More informationORGANISING COMMITTEE
ORGANISING COMMITTEE Dr Anthony Maxwell (Chair) Dr Sarah Vinnicombe (Vice Chair) Dr Sheetal Sharma (Meetings Secretary) Dr Nisha Sharma (Secretary) Dr Julie Cox (Treasurer) Professor Iain Lyburn (Research)
More informationHDAC Inhibitors and PARP inhibitors. Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine
HDAC Inhibitors and PARP inhibitors Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine Histone Acetylation HAT Ac Ac Ac Ac HDAC Ac Ac Ac Ac mrna DACs
More informationa Phase II Randomised Controlled Trial Matthias Guckenberger
Dose-intensified Image-guided Fractionated Stereotactic Body Radiation Therapy for Painful Spinal Metastases (DOSIS) versus Conventional Radiation Therapy: a Phase II Randomised Controlled Matthias Guckenberger
More informationBeyond PARP - Next Generation DDR Therapeutics
Beyond PARP - Next Generation DDR Therapeutics Q2 2017 Safe Harbor Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationSU2C TOP SCIENCE ACCOMPLISHMENTS
SU2C TOP SCIENCE ACCOMPLISHMENTS INTRODUCTION Since our founding in 2008, Stand Up To Cancer has funded 87 team science projects, with budgets ranging from $250,000 for a short research project to over
More informationRecent Advances in Lung Cancer: Updates from ASCO 2016
Recent Advances in Lung Cancer: Updates from ASCO 2016 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/23/2016
More informationPlans for the Precision Cancer Medicine Institute University of Oxford
Plans for the Precision Cancer Medicine Institute University of Oxford STFC & Particle Accelerators and Beams group workshop on particle accelerators for medicine 17 th February 2015 Claire Timlin The
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationDorset Cancer Alliance:
Dorset Cancer Alliance: - Structure and Functions - SSG specification Where are we without a Network? Wessex Strategic Cancer Network Individual Trust Cancer Services Dorset CCG Specialised Commissioning
More informationIntegrating Pain Metrics into Oncologic Clinical and Regulatory Decision-Making. Charles Cleeland MD Anderson Cancer Center
Integrating Pain Metrics into Oncologic Clinical and Regulatory Decision-Making Charles Cleeland MD Anderson Cancer Center Panelists Charles Cleeland, Department Chair, Department of Symptom Research,
More informationRecurrent Ovarian Cancer Phase 1b Results
Recurrent Ovarian Cancer Phase 1b Results December 5 th, 2017 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine
More informationCANM ACMN Annual Meeting April
117 Lu-DOTATATE & 68 Ga-DOTATATE A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of 177 Lu- DOTATATE Treatment, with individualized dosimetry, in Patients with 68 Ga-DOTATATE PET
More information2018 Meeting Programme
2018 Meeting Programme ARR/IRRS Annual Meeting - 25 th 27 th June 2018 Health and Environmental Implications of Multidisciplinary Radiation Research Monday 25 th June - Morning Session 10:00 Registration
More informationImplementing SBRT Protocols: A NRG CIRO Perspective. Ying Xiao, Ph.D. What is NRG Oncology?
Implementing SBRT Protocols: A NRG CIRO Perspective Ying Xiao, Ph.D. What is NRG Oncology? One of five new NCI-supported National Clinical Trials Network (NCTN) groups. NCTN officially started March 1,
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationThe Four R s. Repair Reoxygenation Repopulation Redistribution. The Radiobiology of Small Fraction Numbers. The Radiobiology of Small Fraction Numbers
The Radiobiology of Small Fraction Numbers David J. Brenner, PhD, DSc Center for Radiological Research Columbia University Medical Center djb3@columbia.edu The Radiobiology of Small Fraction Numbers 1.
More informationImmune therapy for women with recurrent ovarian cancer
Immune therapy for women with recurrent ovarian cancer Sarah Adams, MD Associate Professor, Division of Gynecologic Oncology University of New Mexico Comprehensive Cancer Center The problem: overall survival
More information:00-13:00 Industry Satellite Symposium 1 Room A. 13:00-13:30 Welcome reception Hall 1. 13:30-13:45 Opening and welcome Room B
04-10-2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture
More informationNCRI Biomarkers & Imaging CSG Cell-free DNA workshop
NCRI Biomarkers & Imaging CSG Cell-free DNA workshop Workshop Report Christie Education Centre, Manchester 30th January 2014 Sponsored by Workshop summary 86 delegates from a variety of specialities attended
More informationAdvancing innovation towards breakthrough cancer therapies
Advancing innovation towards breakthrough cancer therapies LISTED EURONEXT Paris NASDAQ Copenhagen EPA: ONXEO 39th EORTC PAMM Winter meeting February 218 ASIDNA A FIRST-IN-CLASS COMPOUND TARGETING TUMOR
More information